Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users

Chronic hepatitis C virus (HCV) infection is complicated by hepatic fibrosis. Hypothesizing that early fibrogenic signals may originate in cells susceptible to HCV infection, hepatocyte gene expression was analyzed from persons with chronic HCV at different stages of liver fibrosis. Four HCV‐infecte...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 56; no. 2; pp. 544 - 554
Main Authors Munshaw, Supriya, Hwang, Hyon S., Torbenson, Michael, Quinn, Jeffrey, Hansen, Kasper D., Astemborski, Jacquie, Mehta, Shruti H., Ray, Stuart C., Thomas, David L., Balagopal, Ashwin
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2012
Wiley
Wolters Kluwer Health, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chronic hepatitis C virus (HCV) infection is complicated by hepatic fibrosis. Hypothesizing that early fibrogenic signals may originate in cells susceptible to HCV infection, hepatocyte gene expression was analyzed from persons with chronic HCV at different stages of liver fibrosis. Four HCV‐infected subjects with precirrhosis liver fibrosis (Ishak fibrosis 3‐5) were matched for age, race, and gender to five HCV‐infected subjects with no evidence of fibrosis (Ishak fibrosis 0). Hepatocytes from each subject were isolated from liver biopsies using laser capture microdissection. Transcriptome profiling was performed on hepatocyte RNA using hybridization arrays. We found that hepatocytes in precirrhosis fibrosis were depleted for genes involved in small molecule and drug metabolism, especially butyrylcholinesterase (BCHE), a gene involved in the metabolism of drugs of abuse. Differential expression of BCHE was validated in the same tissues and cross‐sectionally in an expanded cohort of 143 HCV‐infected individuals. In a longitudinal study, serum BCHE activity was already decreased at study inception in 19 fibrosis progressors compared with 20 fibrosis nonprogressors (P < 0.05). Nonprogressors also had decreased BCHE activity over time compared with initial values, but these evolved a median (range) 8.6 (7.8‐11.4) years after the study period inception (P < 0.05). Laser captured portal tracts were enriched for immune related genes when compared with hepatocytes but precirrhosis livers lost this enrichment. Conclusion: Chronic HCV is associated with hepatocyte BCHE loss years before hepatic synthetic function is impaired. These results indicate that BCHE may be involved in the pathogenesis of HCV‐related fibrosis among injection drug users. (HEPATOLOGY 2012)
Bibliography:istex:05810C17A93D5965D1695A0332FD0806EE3C32D1
Supported by National Institutes of Health (NIH) grants NIH DA 016078 (to D.T.), AI 081544 (to A.B.), and EY 001765 (Wilmer Core Grant).
Potential conflict of interest: Dr. Thomas consults for Merck and Gilead. Dr. Balagopal consults for Merck and Paul Capital, LLC.
ark:/67375/WNG-W2K2BWQS-2
ArticleID:HEP25655
fax: +1 410 614 7564
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.25655